Description:
Baricitinib is a selective and orally bioactive inhibitor of JAK1 and JAK2. It has been approved by FDA for the treatment of rheumatoid arthritis (RA).
- Molecular Weight:371.419
- Boiling Point:707.2±70.0 °C at 760 mmHg
- Melting Point:212-215°C
- Purity:>98%
Molecular Formula:
C16H17N7O2S
Canonical SMILES:
CCS(=O)(=O)N1CC(C1)(CC#N)N2C=C(C=N2)C3=C4C=CNC4=NC=N3
InChI:
InChI=1S/C16H17N7O2S/c1-2-26(24,25)22-9-16(10-22,4-5-17)23-8-12(7-21-23)14-13-3-6-18-15(13)20-11-19-14/h3,6-8,11H,2,4,9-10H2,1H3,(H,18,19,20)
InChIKey:
XUZMWHLSFXCVMG-UHFFFAOYSA-N
Appearance:
White to Off-white Solid
Application:
the treatment of rheumatoid arthritis (RA)
Synonyms:
LY3009104; 2-(3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-1-(ethylsulfonyl)azetidin-3-yl)acetonitrile; Olumiant Weitere Informationen finden Sie
hier